Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)

Trial Profile

Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 24 Nov 2021 Results (n=150 ; data cutoff: 22 Mar 2021) assessing safety and efficacy from patients enrolled in EAP in Europe and the Middle East published in the International Journal of Cancer
    • 01 Apr 2021 Results (n=46; data cut-off date between January 2016 and 24 July 2018) assessing a real-world experience with avelumab as a second-line treatment in a subset of Latin America (LATAM) participants enrolled in a global expanded access program for patients with metastatic merkel cell carcinoma, published in the Cancer Immunology, Immunotherapy.
    • 07 Oct 2019 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top